Page last updated: 2024-11-12

n,alpha-diethylphenylethylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N,alpha-diethylphenylethylamine: a monoamine oxidase inhibitor; a component of some dietary supplements [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14833603
CHEBI ID190935
SCHEMBL ID22558398
MeSH IDM0593479

Synonyms (29)

Synonym
n-ethyl-1-phenylbutan-2-amine
CHEBI:190935
(+/-)-n-ethyl-1-phenyl-2-butylamine
119486-07-6
AKOS010037320
ethyl(1-phenylbutan-2-yl)amine
7v4pp58q6t ,
2-ethylamino-1-phenylbutane
n,alpha-depea
benzeneethanamine, n,alpha-diethyl-
n,alpha-diethylphenylethylamine
eapb
unii-7v4pp58q6t
depea
n,.alpha.-diethylbenzeneethanamine
n-ethyl-.alpha.-ethylphenethylamine
benzeneethanamine, n,.alpha.-diethyl-
n,.alpha.-depea
J426.840G ,
n,alpha-diethylphenethylamine
KHWYSUBVXWWBRB-UHFFFAOYSA-N
Q16634226
n,alpha-diethylbenzeneethanamine
DTXSID501017073
EN300-106805
SCHEMBL22558398
CS-0231048
PD046831
Z513799512
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]